The first trial in a massive multidistrict litigation of nearly 14,000 cases involving bleeding risks allegedly caused by the blood thinner Xarelto is scheduled for March, with other trials, each serving as bellwethers, slated for April and May. The first case to be tried involves that of Joseph Boudreaux, who claims he began taking Xarelto in January 2014 as a treatment for his heart condition called atrial fibrillation. About a month later, he was hospitalized for internal bleeding, resulting in multiple blood transfusions. Like the thousands of other lawsuits, Boudreaux claims that Xarelto’s makers, Johnson & Johnson’s Janssen Pharmaceuticals and ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.